Core Viewpoint - Aadi Bioscience, Inc. (AADI) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements [4][6]. - Aadi Bioscience's earnings estimates for the fiscal year ending December 2024 are projected at -$1.92 per share, reflecting a 21.3% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Aadi Bioscience has increased by 40.1%, indicating a positive outlook for the company's earnings [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [7]. - The system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. - Aadi Bioscience's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy